Iron therapy in heart failure patients without anaemia: possible implications for chronic kidney disease patients
نویسندگان
چکیده
Iron deficiency anaemia is a global health problem that manifests as fatigue and poor physical endurance. Anaemia can be caused by dietary iron deficiency, blood loss or a combination of poor iron absorption and ineffective iron mobilization in patients with chronic disease. Nephrologists caring for patients with impaired renal function understand that iron treatment is necessary to provide adequate iron for erythropoiesis during the treatment of overt anaemia. However, a less well-understood health problem is iron deficiency, which creates symptoms that overlap with those of anaemia and often occurs in concert with chronic disease. Recently, several randomized controlled clinical trials have been conducted to investigate the effects of treatment with intravenous iron in heart failure patients with iron deficiency who may or may not also have anaemia. Given that heart and kidney disease are often comorbid, these clinical trials may have implications for the way nephrologists view their patients with iron deficiency. In this article, we review several clinical studies of intravenous iron therapy for patients with iron deficiency and heart failure and discuss possible implications for the treatment of patients with kidney disease.
منابع مشابه
Special issue: iron therapy in patients with chronic kidney disease
Iron deficiency is the most common micronutrient deficiency in the world, affecting approximately one-quarter of the world’s population [1]. It is also very common among patients with chronic kidney disease (CKD), affecting a majority of patients [2–5]. Iron deficiency in CKD arises from a combination of poor dietary iron intake, impaired absorption of iron by the gut, and greater iron losses, ...
متن کاملAnaemia in chronic heart failure: what is its frequency in the UK and its underlying causes?
In two recent studies from Israel, Silverberg and colleagues noted that anaemia was common in chronic heart failure (CHF). 2 Moreover, treatment with combined erythropoietin and intravenous ferrous sulfate not only increased haemoglobin concentrations but, more importantly, was associated with improvements in cardiac function, New York Heart Association (NYHA) functional class, renal function, ...
متن کاملIron treatment and the TREAT trial.
Treatment with erythropoiesis-stimulating agents (ESAs) enables the correction of anaemia in chronic kidney disease (CKD) patients, thus reducing its symptoms and complications. Not only is iron therapy aimed at correcting iron deficiency, but also it is an adjuvant therapy in CKD patients receiving ESAs. Iron stores in CKD patients may be near normal, but there may be insufficient immediately ...
متن کاملBlunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure.
AIMS Anaemia is often observed in patients with chronic heart failure (CHF), and it may be associated with a worse prognosis. Aim of this study was to identify the individual mechanisms of anaemia in CHF patients. METHODS AND RESULTS One hundred and forty-eight consecutive patients with haemoglobin concentration <13 g/dL (if males) or <12 g/dL (if females) were enrolled. Factors responsible f...
متن کاملIntravenous iron therapy in patients with chronic kidney disease: recent evidence and future directions
Current recommendations for the use of intravenous iron therapy in the management of anaemia in patients with chronic kidney disease (CKD) are based on limited clinical evidence. Since the publication of the Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for Anaemia in Chronic Kidney Disease in 2012, a number of randomized clinical trials [notably, the Ferinject A...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 10 شماره
صفحات -
تاریخ انتشار 2017